| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Design Therapeutics, Inc.
13D/A
DSGN · 25056L103
|
4.4% |
11/18/2025
Event 11/14/2025
|
||||
| Logos Global Management LP | 4.4% | |||||
| Logos Global Management GP LLC | 4.4% | |||||
| Logos Global Master Fund LP | 2.6% | |||||
| Logos GP LLC | 2.6% | |||||
| Arsani William | 4.4% | |||||
|
Arvinas, Inc.
13D/A
ARVN · 04335A105
|
3.4% |
10/15/2025
Event 10/13/2025
|
||||
| Logos Global Management LP | 3.4% | |||||
| Logos Global Management GP LLC | 3.4% | |||||
| Logos Global Master Fund LP | 2.7% | |||||
| Logos GP LLC | 2.7% | |||||
| Logos Opportunities Fund IV GP LLC | 0.7% | |||||
| Logos Opportunities Fund IV LP | 0.7% | |||||
| Arsani William | 3.4% | |||||
| Graham Walmsley | 0.7% | |||||
|
Olema Pharmaceuticals, Inc.
13D/A
OLMA · 68062P106
|
4.7% |
5/13/2025
Event 3/18/2025
|
||||
| Logos Global Management LP | 4.7% | |||||
| Logos Global Management GP LLC | 4.7% | |||||
| Arsani William | 4.7% | |||||
| Graham Walmsley | 4.7% | |||||
| Logos Opportunities GP LLC | 1.0% | |||||
| Logos GP LLC | 3.7% | |||||
| Schedule 13G · 17 securities · passive | ||||||
|
Yarrow Bioscience, Inc.
13G/A
YARW · 92941V407
|
10.0% |
11/17/2026
Event 9/30/2026
|
||||
| Logos Global Management LP | 10.0% | |||||
| Logos Global Management GP LLC | 10.0% | |||||
| Logos Global Master Fund LP | 4.9% | |||||
| Logos GP LLC | 4.9% | |||||
| Logos Opportunities Fund V LP | 9.5% | |||||
| Logos Opportunities V GP LLC | 9.5% | |||||
| Arsani William | 10.0% | |||||
| Graham Walmsley | 9.5% | |||||
|
Xilio Therapeutics, Inc.
13G
XLO · 98422T209
|
10.0% |
11/16/2026
Event 6/5/2025
|
||||
| Logos Global Management LP | 10.0% | |||||
| Logos Global Management GP LLC | 10.0% | |||||
| Logos Opportunities Fund IV LP | 10.0% | |||||
| Logos Opportunities IV GP LLC | 10.0% | |||||
| Arsani William | 10.0% | |||||
| Graham Walmsley | 10.0% | |||||
|
Yarrow Bioscience, Inc.
13G/A
YARW · 92941V407
|
10.0% |
11/16/2026
Event 9/30/2026
|
||||
| Logos Global Management LP | 10.0% | |||||
| Logos Global Management GP LLC | 10.0% | |||||
| Logos Global Master Fund LP | 4.9% | |||||
| Logos GP LLC | 4.9% | |||||
| Logos Opportunities Fund V LP | 9.5% | |||||
| Logos Opportunities V GP LLC | 9.5% | |||||
| Arsani William | 10.0% | |||||
| Graham Walmsley | 9.5% | |||||
|
Achieve Life Sciences, Inc.
13G/A
ACHV · 004468500
|
8.6% |
11/16/2026
Event 9/30/2026
|
||||
| Logos Global Management LP | 8.6% | |||||
| Logos Global Management GP LLC | 8.6% | |||||
| Logos Global Master Fund LP | 3.8% | |||||
| Logos GP LLC | 3.8% | |||||
| Logos Opportunities Fund V LP | 4.9% | |||||
| Logos Opportunities V GP LLC | 4.9% | |||||
| Arsani William | 8.6% | |||||
| Graham Walmsley | 4.9% | |||||
|
Longeveron Inc.
13G
LGVN · 54303L302
|
6.3% |
9/10/2026
Event 9/2/2026
|
||||
| Logos Global Management LP | 6.3% | |||||
| Logos Global Management GP LLC | 6.3% | |||||
| Logos Opportunities Fund V LP | 6.3% | |||||
| Logos Opportunities V GP LLC | 6.3% | |||||
| Arsani William | 6.3% | |||||
| Graham Walmsley | 6.3% | |||||
|
Tenax Therapeutics, Inc.
13G/A
TENX · 88032L605
|
3.0% |
5/15/2026
Event 3/31/2026
|
||||
| Logos Global Management LP | 3.0% | |||||
| Logos Global Management GP LLC | 3.0% | |||||
| Logos Global Master Fund LP | 3.0% | |||||
| Logos GP LLC | 3.0% | |||||
| Arsani William | 3.0% | |||||
|
Palatin Technologies Inc
13G/A
PTN · 696077601
|
9.9% |
5/15/2026
Event 3/31/2026
|
||||
| Logos Global Management LP | 9.9% | |||||
| Logos Global Management GP LLC | 9.9% | |||||
| Logos Opportunities Fund IV LP | 9.9% | |||||
| Logos Opportunities Fund IV GP LLC | 9.9% | |||||
| Arsani William | 9.9% | |||||
| Graham Walmsley | 9.9% | |||||
|
iBio, Inc.
13G/A
IBIO · 451033708
|
0% |
5/15/2026
Event 3/31/2026
|
||||
| Logos Global Management LP | 0% | |||||
| Logos Global Management GP LLC | 0% | |||||
| Logos Global Master Fund LP | 0% | |||||
| Logos GP LLC | 0% | |||||
| Arsani William | 0% | |||||
|
Avalo Therapeutics, Inc.
13G/A
AVTX · 05338F306
|
3.2% |
5/15/2026
Event 3/31/2026
|
||||
| Logos Global Management LP | 3.2% | |||||
| Logos Global Management GP LLC | 3.2% | |||||
| Logos Global Master Fund LP | 3.2% | |||||
| Logos GP LLC | 3.2% | |||||
| Arsani William | 3.2% | |||||
|
Minerva Neurosciences, Inc.
13G
NERV · 603380205
|
9.9% |
2/17/2026
Event 12/23/2025
|
||||
| Logos Global Management LP | 9.9% | |||||
| Logos Global Management GP LLC | 9.9% | |||||
| Logos Opportunities Fund IV LP | 7.9% | |||||
| Logos Opportunities Fund IV GP LLC | 7.9% | |||||
| William Arsani | 9.9% | |||||
| Graham G. Walmsley | 7.9% | |||||
|
Verastem, Inc.
13G/A
VSTM · 92337C203
|
4.8% |
11/14/2025
Event 9/30/2025
|
||||
| Logos Global Management LP | 4.8% | |||||
| Logos Global Management GP LLC | 4.8% | |||||
| Logos Global Master Fund LP | 4.8% | |||||
| Logos GP LLC | 4.8% | |||||
| Arsani William | 4.8% | |||||
|
Erasca, Inc.
13G/A
ERAS · 29479A108
|
4.8% |
11/14/2025
Event 9/30/2025
|
||||
| Logos Global Management LP | 4.8% | |||||
| Logos Global Management GP LLC | 4.8% | |||||
| Arsani William | 4.8% | |||||
|
Crescent Biopharma, Inc.
13G/A
CBIO · G2545C104
|
4.1% |
8/14/2025
Event 6/30/2025
|
||||
| Logos Global Management LP | 4.1% | |||||
| Logos Global Management GP LLC | 4.1% | |||||
| Logos Global Master Fund LP | 0.7% | |||||
| Logos GP LLC | 0.7% | |||||
| Arsani William | 4.1% | |||||
|
Prothena Corp Public Ltd Co
13G/A
PRTA · G72800108
|
0% |
8/14/2025
Event 6/30/2025
|
||||
| Logos Global Management LP | 0% | |||||
| Logos Global Management GP LLC | 0% | |||||
| Logos Global Master Fund LP | 0% | |||||
| Logos GP LLC | 0% | |||||
| Arsani William | 0% | |||||
|
Annexon, Inc.
13G/A
ANNX · 03589W102
|
0% |
8/14/2025
Event 6/30/2025
|
||||
| Logos Global Management LP | 0% | |||||
| Logos Global Management GP LLC | 0% | |||||
| Logos Global Master Fund LP | 0% | |||||
| Logos GP LLC | 0% | |||||
| Arsani William | 0% | |||||
|
NextCure, Inc.
13G/A
NXTC · 65343E108
|
0% |
2/14/2025
Event 12/31/2024
|
||||
| Logos Global Management LP | 0% | |||||
| Logos Global Management GP LLC | 0% | |||||
| Logos Global Master Fund LP | 0% | |||||
| Logos GP LLC | 0% | |||||
| Arsani William | 0% | |||||
|
Elevation Oncology, Inc.
13G/A
ELEV · 28623U101
|
0% |
2/14/2025
Event 12/31/2024
|
||||
| Logos Global Management LP | 0% | |||||
| Logos Global Master Fund LP | 0% | |||||
| Logos GP LLC | 0% | |||||
| Arsani William | 0% | |||||
| Logos Global Management GP LLC | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.